Now NICE recommended1
POLIVY + R-Benda is indicated for the treatment of adult patients with relapsed/refractory diffuse
large B-cell lymphoma who are not candidates for haematopoietic stem cell transplant2

MOA, mode of action; NICE, national institute for health and care excellence; R-Benda, rituximab and bendamustine; R/R, relapsed/refractory; DLBCL, diffuse large B-cell lymphoma.

 

References:

  1. NICE Final Appraisal Document. Available at www.nice.org.uk/guidance/gid-ta10463/documents/final-appraisal-determination-document (accessed September 2020).
  2. POLIVY Summary of Product Characteristics.
  3. Sehn LH et al. J Clin Oncol 2020;38(2):155–165.
  4. Dornan D et al. Blood 2009;114(13):2721–2729.
 
M-GB-00000482
Date of preparation: September 2020